Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cells may halt chronic kidney disease
Siamese cat
Researchers hope stem cell therapy may improve organ function in cats with advanced kidney disease.
US researchers launch new clinical trial for cats in advanced stages of disease

Stem cell therapy may be able to slow the progression of kidney disease in cats, US researchers say. A new clinical trial could even have wider implications for human medicine.

Previous studies at Colorado State University (CSU) found stem cells could stabilise the kidneys for cats with early stages of the disease.

A few of the cats with more advanced disease also appeared to benefit, however, showing limited disease progression years after receiving treatment. Encouraged by these results, the research team is now recruiting patients with stage four chronic kidney disease.

"We can't ignore the possibility that stem cells could help those cats too," said Jessica Quimby, leading the research.

Chronic kidney disease is common in older cats but the risk factors are poorly understood and other than a kidney transplant, there is no cure.

Stem cell therapy cannot reverse the kidney scarring that occurs in the later stages of the disease, but CSU researchers hope it may improve the overall function of the kidneys.

Shelley McCarron enrolled her six-year-old Siamese cat Baxter on a CSU study last year. She said: "I believe the treatments have stabilised his kidneys rather than restoring them, but we're grateful nonetheless. It's certainly better to be stabilised than continue to decline".

Patients in the trial will be given three stem cell injections, two weeks apart. Diagnostic tests will be carried out by veterinary surgeons before, during and after the treatment to determine the effect.

Dr Quimby said the research could one day benefit human health, as the disease progresses in a similar way in both humans and cats. "Kidney disease is indeed a huge and growing problem in human medicine. If we saw improvement with cats, we could relate it to curing humans".

Much of the trial costs are covered by Frankie's Fund for Feline Stem Cell Research. The fund was named after a seal point Siamese cat that helped CSU pioneer their stem cell research in 2009. A photo of Frankie is hung in Dr Quimby's office as a reminder of the hope offered by the treatment.

CSU researchers are seeking patients with stable, stage four chronic renal disease. Cats with other diseases will not be eligible. For more information, visit the clinical trial website.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.